<DOC>
	<DOCNO>NCT01056172</DOCNO>
	<brief_summary>This study aim evaluate non-inferiority sustain virologic response peginterferon alfa-2a weight-based ribavirin 16 week compare standard treatment duration 24 week patient achieve rapid virologic response genotype 2 CHC .</brief_summary>
	<brief_title>PegIFN Alfa-2a RBV 16 24 Weeks Patients With Chronic Hepatitis C ( CHC ) 2 With Rapid Virologic Response ( RVR )</brief_title>
	<detailed_description>In recent study ( ACCELERATE trial ) , treatment peginterferon alfa-2a ribavirin ( 800mg/day ) 16 week patient infected HCV genotype 2 3 result low overall sustain virologic response rate treatment standard 24 week regimen . Ribavirin use flat dose ( 800mg/day ) ACCELERATE trial . But , previous study use weight-based dose ribavirin ( 800-1400mg/day ) show treatment duration 16 week effective 24 week regimen HCV genotype 2 patient RVR . But , small number patient enrol study argue logically ACCELERATE trial . In study , aim confirm non-inferiority peginterferon alfa-2a weight-based ribavirin 16 week compare standard treatment duration 24 week patient achieve rapid virologic response genotype 2 CHC .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Age old 18 year old 2 . Serologic evidence chronic hepatitis C infection antiHCV antibody test 3 . Detectable serum quantitative HCVRNA 4 . HCV genotype 2 ( VERSANT HCV Genotype Assay ( LIPA ) ) 5 . Patients never treat traditional interferon plus ribavirin peginterferon plus ribavirin 1 . Coinfection hepatitis B and/or human immunodeficiency virus ( HIV ) 2 . History evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) 3 . Decompensated liver disease ( ChildPugh class B C ) 4 . Neoplastic disease within 5 year 5 . Evidence drug abuse ( include excessive alcohol consumption ) within one year study entry 6 . Women ongoing pregnancy breast feed 7 . Hgb &lt; 11 g/dL woman &lt; 12 g/dL men screen 8 . Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 90,000 cells/mm3 screen 9 . Serum creatinine level &gt; 1.5 time upper limit normal screen 10 . Serum alphafetoprotein &gt; 100 ng/mL 11 . History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication major tranquilizer therapeutic dos major depression psychosis , respectively , least 3 month previous time history follow : suicidal attempt , hospitalization psychiatric disease , period disability due psychiatric disease 12 . History immunologically mediate disease , chronic pulmonary disease associate functional limitation , severe cardiac disease , major organ transplantation evidence severe illness , malignancy , condition would make patient , opinion investigator , unsuitable study 13 . History evidence bleed esophageal varix condition consistent decompensated liver disease 14 . History severe seizure disorder current anticonvulsant use 15 . Evidence severe retinopathy ( e.g . CMV retinitis , macula degeneration ) 16 . Inability unwillingness provide inform consent abide requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Rapid virologic response</keyword>
	<keyword>Sustained virologic response</keyword>
	<keyword>Peginterferon alfa-2a</keyword>
	<keyword>Ribavirin</keyword>
</DOC>